Information on results of RFP - 025130 - IN VIVO ANTI-CANCER EFFICACY STUDY USING MATERIAL FROM DONORS

In connection with the project „Clinical trial of the first phase (Ia/Ib) of a fusion protein with a dual anticancer mechanism”, financed from Medical Research Agency (nr. 2022/ABM/05/00006-00) operating under §8 of the subsidy agreement, Adamed Pharma informs that due to project’s reasons, RFP was canceled.